DIPYRIDAMOLE - Generic Drug Details

What are the generic sources for dipyridamole and what is the scope of freedom to operate?

Dipyridamole is the generic ingredient in three branded drugs marketed by Chartwell Injectable, Dr Reddys, Eugia Pharma Speclts, Fresenius Kabi Usa, Hikma, Hospira, Boehringer Ingelheim, Ani Pharms, Barr, Chartwell Rx, Glenmark Generics, Impax Labs, Oxford Pharms, Purepac Pharm, Rising, Watson Labs, and Zydus Pharms Usa Inc, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for dipyridamole. Nine suppliers are listed for this compound.

Summary for DIPYRIDAMOLE

US Patents:	0
Tradenames:	3
Applicants:	17
NDAs:	24
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	148
Clinical Trials:	79
Patent Applications:	6,750
Drug Prices:	Drug price trends for DIPYRIDAMOLE
What excipients (inactive ingredients) are in DIPYRIDAMOLE?	DIPYRIDAMOLE excipients list
DailyMed Link:	DIPYRIDAMOLE at DailyMed

See drug prices for DIPYRIDAMOLE

Recent Clinical Trials for DIPYRIDAMOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guo-Qing Jiang	N/A
Clear Creek Bio, Inc.	Phase 2
Rutgers, The State University of New Jersey	Phase 3

See all DIPYRIDAMOLE clinical trials

Pharmacology for DIPYRIDAMOLE

Drug Class	Platelet Aggregation Inhibitor
Physiological Effect	Decreased Platelet Aggregation

Medical Subject Heading (MeSH) Categories for DIPYRIDAMOLE

Phosphodiesterase Inhibitors

Platelet Aggregation Inhibitors

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for DIPYRIDAMOLE

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for DIPYRIDAMOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040898-002	Apr 23, 2008		DISCN	No	No
Chartwell Rx	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040898-001	Apr 23, 2008		DISCN	No	No
Fresenius Kabi Usa	DIPYRIDAMOLE	dipyridamole	INJECTABLE;INJECTION	074956-001	Sep 30, 1998		DISCN	No	No
Impax Labs	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040782-002	Jul 18, 2007	AB	RX	No	No
Barr	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	087717-001	Oct 3, 1990	AB	RX	No	No
Purepac Pharm	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	089425-001	Jul 12, 1990		DISCN	No	No
Glenmark Generics	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	089000-001	Feb 5, 1991		DISCN	No	No

DIPYRIDAMOLE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Dipyridamole

Introduction

Dipyridamole, a medication primarily used as an antiplatelet agent, has been gaining significant traction in the pharmaceutical market due to its efficacy in preventing thrombosis and treating cardiovascular diseases. Here, we delve into the market dynamics and financial trajectory of dipyridamole, highlighting key drivers, challenges, and projections.

Market Size and Growth Projections

The dipyridamole market was valued at USD 1.81 billion in 2023 and is anticipated to reach USD 2.94 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 7.56% from 2024 to 2031[1].

Segmentation of the Market

The market is segmented based on type (tablets, capsules, injectable solution) and application (thrombosis prophylaxis, coronary artery disease), as well as geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa)[1].

Drivers of Market Growth

Increasing Prevalence of Cardiovascular Diseases

The rising incidence of heart attacks and strokes globally is a significant driver of the dipyridamole market. Cardiovascular diseases are more prevalent among the elderly, and the aging population worldwide is increasing the demand for dipyridamole[1].

Technological Advancements

Advancements in pharmaceutical technologies have led to improved drug delivery methods and formulations, enhancing the safety and efficacy of dipyridamole. This has increased its prescription rates among medical professionals[1].

Growing Awareness of Preventative Care

There is a growing awareness among patients about the importance of preventative medication and cardiovascular health. This increased awareness is driving the demand for dipyridamole[1].

Increased Healthcare Expenditure and R&D Investments

Rising healthcare costs and increased investments in research and development by pharmaceutical companies are also contributing to the market's growth[1].

Geographical Market Dynamics

Regional Market Performance

The Asia-Pacific region is expected to show significant growth due to the large population and increasing healthcare expenditure. North America and Europe are also key markets, driven by advanced healthcare systems and high awareness of cardiovascular health[1].

Competitive Landscape

The dipyridamole market is competitive, with several key players such as Boehringer Ingelheim, Sanofi, Aspen Pharmacare, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Bayer AG, Bristol-Myers Squibb, GlaxoSmithKline plc, Merck & Co., Inc., and Apotex Inc.[1].

Cost-Effectiveness and Economic Impact

Dipyridamole, especially when combined with aspirin, is considered cost-effective in preventing cardiovascular events. For instance, the combination of dipyridamole and aspirin is equally cost-effective, with a cost of US$93 per Disability-Adjusted Life Year (DALY) averted[2].

Market Challenges

Regulatory Environment

The pharmaceutical industry is heavily regulated, and changes in regulatory policies can impact the market dynamics of dipyridamole. Strict approval processes and compliance requirements can pose challenges to new entrants and existing players alike.

Competition from Alternative Treatments

The presence of other antiplatelet medications and treatments can pose a competitive threat to dipyridamole. However, its established efficacy and safety profile continue to make it a preferred choice among healthcare providers.

Financial Performance and Projections

Revenue Growth

The revenue growth of the dipyridamole market is expected to be robust, driven by the increasing demand for antiplatelet medications. The market's CAGR of 7.56% from 2024 to 2031 indicates a strong financial trajectory[1].

Investment in R&D

Pharmaceutical companies are investing heavily in research and development to improve the formulations and delivery methods of dipyridamole. This investment is expected to yield better products and further drive market growth[1].

Market Opportunities

Emerging Markets

Emerging markets, particularly in the Asia-Pacific region, offer significant opportunities for growth. Increasing healthcare expenditure and a growing awareness of cardiovascular health in these regions are expected to drive the demand for dipyridamole.

Innovative Formulations

The development of innovative formulations, such as the combination of ginkgo leaf extract and dipyridamole injections, is another area of opportunity. These new formulations can enhance the market's growth by offering better therapeutic outcomes[4].

Conclusion

The dipyridamole market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and growing awareness of preventative care. With a projected CAGR of 7.56% from 2024 to 2031, the market is expected to reach USD 2.94 billion by 2031. Key players and emerging markets will continue to play a crucial role in shaping the market dynamics of dipyridamole.

Key Takeaways

• The dipyridamole market was valued at USD 1.81 billion in 2023 and is expected to reach USD 2.94 billion by 2031.
• The market is growing at a CAGR of 7.56% from 2024 to 2031.
• Key drivers include the increasing prevalence of cardiovascular diseases, technological advancements, and growing awareness of preventative care.
• The market is segmented by type, application, and geographical regions.
• Emerging markets and innovative formulations offer significant growth opportunities.

FAQs

What is the current market size of dipyridamole?

The dipyridamole market was valued at USD 1.81 billion in 2023[1].

What is the projected growth rate of the dipyridamole market?

The market is expected to grow at a CAGR of 7.56% from 2024 to 2031[1].

What are the main drivers of the dipyridamole market?

The main drivers include the increasing prevalence of cardiovascular diseases, technological advancements, and growing awareness of preventative care[1].

Which regions are expected to show significant growth in the dipyridamole market?

The Asia-Pacific region, along with North America and Europe, is expected to show significant growth[1].

What are the key segments of the dipyridamole market?

The market is segmented by type (tablets, capsules, injectable solution), application (thrombosis prophylaxis, coronary artery disease), and geographical regions[1].

Sources

1. Market Research Intellect, "Dipyridamole Market Size and Projections - Market Research Intellect," October 2024.
2. NCBI, "Intervention Cost-Effectiveness: Overview of Main Messages."
3. FTC, "Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets."
4. Market Research Intellect, "Ginkgo Leaf Extract and Dipyridamole Injection Market Size, Scope."